PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2207 Views
-
Last post by NHE
-
- 0 Replies
- 1061 Views
-
Last post by NHE
-
- 0 Replies
- 10678 Views
-
Last post by NHE
-
- 0 Replies
- 2108 Views
-
Last post by Firidion
-
- 1 Replies
- 1362 Views
-
Last post by vesta
-
- 0 Replies
- 2100 Views
-
Last post by frodo
-
- 0 Replies
- 2019 Views
-
Last post by NHE
-
- 0 Replies
- 1525 Views
-
Last post by NHE
-
- 4 Replies
- 2527 Views
-
Last post by JohnC777